NASDAQ:NTGNNeon Therapeutics Stock Price, Forecast & News

Neon Therapeutics' stock was trading at $1.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NTGN shares have increased by 93.1% and is now trading at $3.07. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Neon Therapeutics.

Neon Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Neon Therapeutics.

Neon Therapeutics Inc (NASDAQ:NTGN) announced its quarterly earnings data on Monday, March, 2nd. The company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.66) by $0.03. View Neon Therapeutics' earnings history.

5 brokers have issued 1-year price objectives for Neon Therapeutics' shares. Their forecasts range from $2.18 to $15.00. On average, they anticipate Neon Therapeutics' share price to reach $9.05 in the next year. This suggests a possible upside of 194.6% from the stock's current price. View analysts' price targets for Neon Therapeutics.

Media coverage about NTGN stock has trended very negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neon Therapeutics earned a news impact score of -3.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutNeon Therapeutics.

Neon Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 743,900 shares, an increase of 15.4% from the April 15th total of 644,800 shares. Based on an average daily trading volume, of 449,800 shares, the days-to-cover ratio is presently 1.7 days. Approximately 4.9% of the shares of the company are short sold. View Neon Therapeutics' Current Options Chain.

Some companies that are related to Neon Therapeutics include Eiger Biopharmaceuticals (EIGR), Cellular Biomedicine Group (CBMG), CASI Pharmaceuticals (CASI), Tcr2 Therapeutics (TCRR), ADMA Biologics (ADMA), Gritstone Oncology (GRTS), Verona Pharma (TARA), Sutro Biopharma (STRO), Vaxart (VXRT), Axcella Health (AXLA), Pluristem Therapeutics (PSTI), GENFIT S A/ADR (GNFT), Brainstorm Cell Therapeutics (BCLI), Fennec Pharmaceuticals (FENC) and Jounce Therapeutics (JNCE). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neon Therapeutics investors own include Anavex Life Sciences (AVXL), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Aduro BioTech (ADRO), Agile Therapeutics (AGRX), Selecta Biosciences (SELB), Melinta Therapeutics (MLNT), Nabriva Therapeutics (NBRV), Vaxart (VXRT) and Zynerba Pharmaceuticals (ZYNE).

(NTGN) raised $101 million in an initial public offering on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as the underwriters for the IPO and Oppenheimer was co-manager.

Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN."

Neon Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.85%), Athanor Capital LP (1.89%), Maven Securities LTD (1.32%), State Street Corp (0.95%), Geode Capital Management LLC (0.73%) and Moneta Group Investment Advisors LLC (0.35%). Company insiders that own Neon Therapeutics stock include Access Industries Holdings Llc and Richard Gaynor. View institutional ownership trends for Neon Therapeutics.

NTGN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, UBS Group AG, and Deutsche Bank AG. Company insiders that have sold Neon Therapeutics company stock in the last year include Access Industries Holdings Llc, and Richard Gaynor. View insider buying and selling activity for Neon Therapeutics.

NTGN stock was bought by a variety of institutional investors in the last quarter, including Athanor Capital LP, Maven Securities LTD, Moneta Group Investment Advisors LLC, State Street Corp, Geode Capital Management LLC, Terril Brothers Inc., Nuveen Asset Management LLC, and Acadian Asset Management LLC. View insider buying and selling activity for Neon Therapeutics.

Shares of NTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NTGN stock can currently be purchased for approximately $3.07.

Neon Therapeutics has a market capitalization of $88.93 million. The company earns $-79,780,000.00 in net income (profit) each year or ($2.86) on an earnings per share basis. Neon Therapeutics employs 102 workers across the globe.

The official website for Neon Therapeutics is www.neontherapeutics.com.

Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected]